Original Research
Accepted on 30 Apr 2026
EZH2 Blockade Reverses Doxorubicin Resistance by Inducing Metabolic Vulnerability and Enhancing DNA Damage in Breast Cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
- 147 views
Original Research
Accepted on 30 Apr 2026
in Pharmacology of Anti-Cancer Drugs
Mini Review
Published on 13 May 2026
in Hematologic Malignancies
Original Research
Published on 03 Sep 2021
in Molecular and Cellular Oncology
Original Research
Published on 03 Feb 2026
in Cancer Immunity and Immunotherapy
Original Research
Published on 11 Sep 2023
in Hematologic Malignancies
Brief Research Report
Published on 15 Apr 2026
in Pediatric Oncology